Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M.Y. Lee; Keith A. Gillis; Katriona J.M. Brooksbank; Sarah Allwood-Spiers; Pauline Hall Barrientos; Kirsty Wetherall; Giles Roditi; Bashair Alhummiany; Colin Berry; Ross T. Campbell; Victor Chong; Liz Coyle; Kieran F. Docherty; John G. Dreisbach; Bernd Kuehn; Catherine Labinjoh; Ninian N. Lang; Vera Lennie; Kenneth Mangion; Alex McConnachie; Clare L. Murphy; Colin J. Petrie; John R. Petrie; Kanishka Sharma; Steven Sourbron; Iain A. Speirits; Joyce Thompson; Paul Welsh; Rosemary Woodward; Ann Wright; Aleksandra Radjenovic; John J.V. McMurray; Pardeep S. Jhund; Mark C. Petrie; Naveed Sattar; Patrick B. Mark

Journal ArticleOPEN ACCESS

Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Circulation (2022) 146(4) 364-367

DOI: 10.1161/CIRCULATIONAHA.122.059851

12Citations

32Readers

Author supplied keywords

Cite

CITATION STYLE

APA

Lee, M. M. Y., Gillis, K. A., Brooksbank, K. J. M., Allwood-Spiers, S., Hall Barrientos, P., Wetherall, K., … Mark, P. B. (2022). Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 146(4), 364–367. https://doi.org/10.1161/CIRCULATIONAHA.122.059851

Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Author supplied keywords

Cite

Register to see more suggestions